Evotec (EVO) said Wednesday it signed a nonbinding agreement with Sandoz for the potential sale of the Just - Evotec Biologics EU site in Toulouse, France, for roughly $300 million in cash.
Under the proposed deal, Sandoz would assume full ownership of the site, with Evotec to retain economic upside via revenue, milestones and royalty optionality.
The deal terms include further technology-related consideration, future development revenue, milestones and product royalties, Evotec said.
The company's shares were up 4.5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.